These findings suggest that BLCA patients with high FAM174B may not only respond poorly to ICIs but could potentially experience accelerated disease progression, warranting caution in therapeutic decision-making for this patient subset. The gene discussed is FAM174B; the disease is bladder transitional cell carcinoma.